🔎 Trials Near Me

Beranda › Glioblastoma › Ohio › Columbus

Uji klinis Glioblastoma di Columbus, OH

14 studi untuk Glioblastoma mencari peserta di lokasi sekitar Columbus (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

Menerima pesertaFase 1/2
  • Ohio State University Comprehensive Cancer Center, Columbus
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT05432804

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Menerima pesertaFase 2
  • Ohio State University, Columbus
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07326566

Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

Menerima pesertaFase 3
  • The Ohio State University, Columbus
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07195591

Targeted Pediatric High-Grade Glioma Therapy

Menerima pesertaStudi observasional
  • Nationwide Children's Hospital, Columbus
12 Months – 39 Years · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT05839379

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Menerima pesertaFase 1
  • Ohio State University Comprehensive Cancer Center, Columbus
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT06860594

Study of Olutasidenib and Temozolomide in HGG

Menerima pesertaFase 2
  • Nationwide Children's Hospital, Columbus
Usia 12 hingga 39 · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT06161974

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma

Menerima peserta
  • Ohio State University Medical Center, Columbus
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 21 Jul 2026 · NCT06910306

Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma

Menerima pesertaFase 2
  • Ohio State University, Columbus
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 17 Jul 2026 · NCT07225621

DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

Menerima pesertaFase 2
  • The Ohio State University Comprehensive Cancer Center, Columbus
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Jul 2026 · NCT06805305

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Menerima pesertaFase awal 1Sukarelawan sehat diterima
  • Nationwide Children's Hospital, Columbus
Usia 1 hingga 21 · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT06333899

Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma

Menerima pesertaFase 1/2
  • Ohio State University Hospital, Columbus
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 12 Jun 2026 · NCT07346144

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Menerima pesertaFase 2
  • Nationwide Children's Hospital, Columbus
12 Months – 39 Years · Semua jenis kelamin · Diperbarui 29 Mei 2026 · NCT05843253

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Menerima pesertaFase 1/2
  • Ohio State University Comprehensive Cancer Center, Columbus
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Apr 2026 · NCT06810544

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Menerima pesertaStudi observasional
  • Massive Bio SYNERGY-AI site, Columbus
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774

Uji klinis Glioblastoma di kota lain

Studi lain di Columbus

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.